DAIC

FEBRUARY 2, 2024

Photo: Edwards Lifesciences milla1cf Fri, 02/02/2024 - 09:33 February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Tricuspid 100

Tricuspid Quality of Life Bicuspid/Mitral Innovation 100

Circulation

APRIL 25, 2024

Tricuspid valve disease is an often underrecognized clinical problem that is associated with significant morbidity and mortality. Unfortunately, patients will often present late in their disease course with severe right-sided heart failure, pulmonary hypertension, and life-limiting symptoms that have few durable treatment options.

Tricuspid 80

Tricuspid Pacemaker Heart Failure Pulmonary 80

European Journal of Heart Failure

MARCH 7, 2024

Changes in right ventricular (RV) function and clinical outcomes after tricuspid transcatheter edge-to-edge repair (T-TEER). The primary outcome was a composite of mortality and hospitalization due to heart failure within 1 year. Patients with an increase in RVFAC from baseline to the follow-up were considered as RV responders.

Tricuspid 76

Tricuspid Outcomes Heart Failure Hospital 76

European Journal of Heart Failure

NOVEMBER 26, 2024

Right ventricular reverse remodelling after transcatheter tricuspid valve intervention (TTVI). Optimal tricuspid regurgitation (TR) reduction is critical for right ventricular reverse remodelling. Mortality was analysed at 1year after transcatheter tricuspid valve intervention (TTVI).

Tricuspid 40

Tricuspid Heart Failure Exercise Research 40

DAIC

APRIL 9, 2024

Image courtesy of UC Davis Health milla1cf Tue, 04/09/2024 - 16:47 April 9, 2024 — UC Davis Health cardiology team members are among the first in the country to treat patients with tricuspid regurgitation , or a leaky heart valve, by using a groundbreaking catheter. Tricuspid regurgitation affects an estimated 1.6

Tricuspid 111

Tricuspid Heart Valves Bicuspid/Mitral Quality of Life 111

Frontiers in Cardiovascular Medicine

NOVEMBER 17, 2024

BackgroundAnemia is a common complication in patients with heart failure and is associated with left ventricular systolic dysfunction.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Tricuspid Atrial Fibrillation 59

DAIC

JUNE 11, 2024

Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Kodali, MD, pictured here, is one of the members of its leadership team, and director of the Structural Heart and Valve Center at CUIMC/NewYork-Presbyterian Hospital.

Tricuspid 52

Tricuspid Bicuspid/Mitral Heart Valves Innovation 52

European Journal of Heart Failure

FEBRUARY 26, 2025

Proposed approach for clinical management and therapeutic optimization in patients with heart failure with reduced ejection fraction and low blood pressure. Low blood pressure with major or mild symptoms. **SBP SBP <80mmHg or symptomatic low BP or asymptomatic low BP.

Blood Pressure 58

Blood Pressure Heart Failure Aortic valve TAVR 58

DAIC

MAY 3, 2024

Atlantic Health System’s Morristown Medical Center Treats First Patient in New Jersey with Edwards’ EVOQUE Tricuspid Valve Replacement 3. 24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack 10. New Study Reveals 65 and Older Population Lowered Blood Pressure, Cholesterol and Weight Using Mobile Technology 2.

Blood Pressure 105

Blood Pressure Angioplasty Heart Attack Heart attacks 105

Medical Xpress - Cardiology

MARCH 13, 2025

Atrial functional mitral regurgitation (AFMR) is a common type of MR linked to high rates of heart failure, highlighting the need to understand its prognostic factors.

Tricuspid 40

Tricuspid Heart Failure Bicuspid/Mitral Heart Disease 40

All About Cardiovascular System and Disorders

MARCH 30, 2024

Transcript of the video: Ebstein’s Anomaly is one of the cyanotic congenital heart disease in which survival to adult life is common. In Ebstein’s anomaly, there is downward or apical displacement of posterior and septal tricuspid leaflets. Anterior leaflet is elongated and sail like.

Tricuspid 52

Tricuspid Arrhythmia Congenital Heart Disease Electrophysiology 52

HeartRhythm

APRIL 30, 2024

Tricuspid valve (TV) function and its relation to cardiac device implantation is an essential consideration. Recent studies have shown a 5% increase in prevalence of moderate to severe tricuspid valve regurgitation (TR) one year post endocardial lead implantation.

Tricuspid 40

Tricuspid Heart Failure Hospital 40

Circulation: Cardiovascular Interventions

NOVEMBER 9, 2023

Background:There are limited data about changes in cardiac function (cardiac reverse remodeling) and heart failure indices after transcatheter tricuspid valve-in-valve replacement (TT-VIVR).

Congenital Heart Disease 40

Congenital Heart Disease Tricuspid Heart Failure Congenital 40

Medical Xpress - Cardiology

NOVEMBER 25, 2024

Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR), according to a study published online Nov. 6 in JAMA Cardiology.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Tricuspid 40

DAIC

DECEMBER 22, 2023

Tricuspid regurgitation (TR) is a common and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Topaz is an innovative, minimally invasive device designed specifically to help patients suffering from severe TR, without the need for open heart surgery.

Tricuspid 59

Tricuspid Pacemaker Heart Valves Open-Heart Surgery 59

DAIC

JUNE 5, 2024

The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.

Critical Care 105

Critical Care Tricuspid Innovation Bicuspid/Mitral 105

European Journal of Heart Failure

MARCH 11, 2024

Abstract Aims The aim of this study was to assess the pathophysiological implications of severe tricuspid regurgitation (TR) in patients with heart failure with preserved ejection fraction (HFpEF) by using tricuspid transcatheter edge-to-edge repair (T-TEER) as a model of right ventricular (RV) volume overload relief.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Tricuspid Heart Failure Physiology 40

American College of Cardiology

JULY 2, 2024

Many patients with severe, symptomatic tricuspid regurgitation (TR) may also present with advanced heart failure with preserved ejection fraction (HFpEF), and treatments for each condition may impact the other condition.

Preserved Ejection Fraction 69

Preserved Ejection Fraction Tricuspid Heart Failure Article 69

European Journal of Heart Failure

FEBRUARY 19, 2025

Prognostic impact of severe tricuspid regurgitation (TR) in patients with atrial functional mitral regurgitation (AFMR). Abstract Aims Tricuspid regurgitation (TR) is often seen in patients with atrial functional mitral regurgitation (AFMR). The primary endpoint was a composite of heart failure hospitalization and all-cause mortality.

Tricuspid 40

Tricuspid Bicuspid/Mitral Atrial Fibrillation Heart Failure 40

American College of Cardiology

MARCH 27, 2024

In this week’s View, Dr. Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aortic stenosis.

Heart Failure 48

Heart Failure Stenosis Aortic Tricuspid 48

European Journal of Heart Failure

DECEMBER 2, 2024

If hemodynamic overload is sustained, it can progress to a maladaptive state and lead eventually to heart failure. Aims Conventional parameters of right ventricular (RV) function are load-dependent and therefore do not accurately reflect contractility in patients with relevant tricuspid regurgitation (TR).

Tricuspid 40

Tricuspid Heart Failure Pulmonary Hospital 40

Circulation

NOVEMBER 11, 2024

EECP can improve exercise tolerance, reduce anginal symptoms, and enhance endothelial function, offering a potential alternative for patients with ischemic HFrEF awaiting heart transplantation.Description of a Case:A 58-year-old Hispanic female with a history of severe CAD, type II DM, hyperlipidemia, and CVA.

Heart Transplant 75

Heart Transplant Transplant Angina Heart Failure 75

Open Heart

SEPTEMBER 11, 2023

Objectives Inferior vena cava (IVC) diameter may be a surrogate for volume status in acute decompensated heart failure (ADHF). In multivariable Cox regression only IVC diameter (p<0.001), presence of tricuspid regurgitation (p=0.02) and NYHA class III/IV (p<0.001) independently predicted ADHF rehospitalisation within 1 year.

Heart Failure 52

Heart Failure Tricuspid Echocardiogram Pulmonary 52

Heart BMJ

DECEMBER 15, 2023

Aims Identifying clinical and echocardiographic parameters associated with improvement in systolic function in outpatients with heart failure with reduced ejection fraction (HFrEF) could lead to more targeted treatment improving systolic function and outcome. to 7.51, p=0.006).

Heart Failure 45

Heart Failure Outpatient Tricuspid Cardiomyopathy 45

Open Heart

DECEMBER 15, 2022

Introduction Isolated tricuspid valve surgery (TVS) may be associated with high morbidity and mortality. Patients with congenital heart disease, infective endocarditis and those who underwent concomitant valve or pericardial surgery were excluded. The primary outcome was a composite of mortality and congestive heart failure at 1 year.

Tricuspid 52

Tricuspid Outcomes Congenital Heart Disease Congenital 52

Circulation: Heart Failure

NOVEMBER 5, 2024

Circulation: Heart Failure, Ahead of Print.

Heart Failure 40

Heart Failure Tricuspid Circulation 40

The American Journal of Cardiology

MARCH 2, 2024

Publication date: Available online 2 March 2024 Source: The American Journal of Cardiology Author(s): Piotr Nikodem Rudziński, Jan Henzel, Adam Witkowski, Maciej Dąbrowski, Zenon Huczek, Wojciech Wojakowski, Radosław Targoński, Dariusz Jagielak, Paweł Kralisz, Marcin Demkow

Tricuspid 52

Tricuspid Heart Failure 52

Circulation

NOVEMBER 11, 2024

Tricuspid regurgitation was reduced to ≤moderate in 82.5% Patients experienced significant clinical improvements in New York Heart Association (NYHA) functional class I/II (32.6% Kaplan-Meier estimated of survival and freedom from heart failure re-hospitalization were 97.8% female, mean TRISCORE 5.3±2.1). 18.5mL vs 67.6±19.8mL,

Tricuspid 40

Tricuspid Quality of Life Heart Failure Cardiomyopathy 40

European Journal of Heart Failure

DECEMBER 7, 2023

ABSTRACT Background Left atrial (LA) myopathy is increasingly recognized as an important phenotypic trait in heart failure (HF) with preserved ejection fraction (HFpEF). There were 94 patients with events over a median follow-up of 2.9 (IQR 2.92, p = 0.01).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Exercise Atrial Fibrillation 40

American College of Cardiology

JULY 24, 2024

In this week’s View, Dr. Eagle looks at a study comparing three diuretic regimens in ambulatory congested heart failure (HF) patients (DEA-HF).

Tricuspid 48

Tricuspid Heart Failure Article 48

European Journal of Heart Failure

NOVEMBER 8, 2023

Abstract Aim Functional or secondary tricuspid regurgitation (STR) is the most common phenotype of tricuspid regurgitation (TR) with atrial STR (ASTR) and ventricular STR (VSTR) being recently identified as two distinct entities. ASTR vs. VSTR) are lacking.

Tricuspid 40

Tricuspid Outcomes Atrial Fibrillation Pulmonary 40

Frontiers in Cardiovascular Medicine

JULY 30, 2024

Traditional transvenous pacemakers consist of a pacemaker generator usually positioned surgically in the upper left chest on the pectoral muscle fascia and one or more leads positioned through the veins to the right atrium and across the tricuspid valve to the right ventricular apex.

Pacemaker 52

Pacemaker Tricuspid Bradycardia Heart Failure 52

Circulation: Heart Failure

SEPTEMBER 12, 2023

Circulation: Heart Failure, Ahead of Print.

Tricuspid 40

Tricuspid Heart Failure Circulation 40

Circulation

NOVEMBER 11, 2024

Background:Tricuspid regurgitation (TR) is a common occurrence in patients with heart failure (HF), and its role in disease progression has gained attention in recent years. Circulation, Volume 150, Issue Suppl_1 , Page A4142159-A4142159, November 12, 2024.

Heart Failure 40

Heart Failure Tricuspid Outcomes Medicare 40

Journal of Cardiovascular Electrophysiology

OCTOBER 21, 2024

Abstract Introduction Catheter ablation for atrial fibrillation (AF) reduces heart failure (HF) hospitalization in patients with HF with preserved ejection fraction (HFpEF). However, the long-term outcomes and subclinical HF after nonparoxysmal AF ablation in HFpEF patients have not been fully evaluated.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

Journal of the American Heart Association

FEBRUARY 19, 2025

Journal of the American Heart Association, Ahead of Print. Similar findings were obtained when allcause death was considered as the end point.ConclusionsIn patients with chronic heart failure and left ventricular ejection fraction &lt;50%, TAPSE, and RVFAC are more accurate than S in predicting the risk of cardiac and allcause death.

Heart Failure 40

Heart Failure Tricuspid Outpatient 40

European Journal of Heart Failure

DECEMBER 13, 2023

6MWD, 6-min walk distance; CI, cardiac index; CPI, cardiac power index; LVEF, left ventricular ejection fraction; PA, pulmonary artery; PCW, pulmonary capillary wedge; RA, right atrial; TAPSE, tricuspid annular plane systolic excursion; TSAT, transferrin saturation; VO 2 , oxygen consumption.

Heart Failure 40

Heart Failure Heart Transplant Transplant Tricuspid 40